Avita Medical, Inc. RCEL
We take great care to ensure that the data presented and summarized in this overview for AVITA Medical, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RCEL
View all-
Black Rock Inc. New York, NY1.75MShares$14.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.41MShares$11.4 Million0.0% of portfolio
-
State Street Corp Boston, MA941KShares$7.62 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA543KShares$4.4 Million0.0% of portfolio
-
Awm Investment Company, Inc. New York, NY497KShares$4.03 Million1.19% of portfolio
-
Silvercrest Asset Management Group LLC New York, NY242KShares$1.96 Million0.03% of portfolio
-
Northern Trust Corp Chicago, IL218KShares$1.77 Million0.0% of portfolio
-
Center Book Partners LP Greenwich, CT145KShares$1.18 Million0.17% of portfolio
-
Aqr Capital Management LLC Greenwich, CT90.6KShares$733,8600.0% of portfolio
-
Goldman Sachs Group Inc New York, NY80.9KShares$655,3300.0% of portfolio
Latest Institutional Activity in RCEL
Top Purchases
Top Sells
About RCEL
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
Insider Transactions at RCEL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2024
|
David D O'Toole CFO |
BUY
Open market or private purchase
|
Direct |
1,250
+3.22%
|
$21,250
$17.41 P/Share
|
|
Dec 26
2023
|
James Corbett CEO |
SELL
Open market or private sale
|
Direct |
1,445
-11.09%
|
$18,785
$13.29 P/Share
|
|
Dec 13
2023
|
Jeremy Curnock Cook |
SELL
Open market or private sale
|
Direct |
2,518
-10.89%
|
$30,216
$12.27 P/Share
|
|
Dec 12
2023
|
David D O'Toole CFO |
BUY
Open market or private purchase
|
Direct |
950
+5.15%
|
$11,400
$12.45 P/Share
|
|
Dec 01
2023
|
David D O'Toole CFO |
BUY
Open market or private purchase
|
Direct |
500
+2.94%
|
$5,000
$10.68 P/Share
|
|
Nov 30
2023
|
Donna Shiroma General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
1,469
+3.25%
|
$13,221
$9.06 P/Share
|
|
Nov 30
2023
|
David D O'Toole CFO |
BUY
Grant, award, or other acquisition
|
Direct |
1,034
+6.06%
|
$9,306
$9.06 P/Share
|
|
Nov 21
2023
|
David D O'Toole CFO |
BUY
Open market or private purchase
|
Direct |
2,000
+6.46%
|
$20,000
$10.28 P/Share
|
|
Nov 16
2023
|
David D O'Toole CFO |
BUY
Open market or private purchase
|
Direct |
1,000
+7.69%
|
$12,000
$12.15 P/Share
|
|
Nov 15
2023
|
David D O'Toole CFO |
BUY
Open market or private purchase
|
Direct |
2,000
+7.74%
|
$24,000
$12.85 P/Share
|
|
Nov 14
2023
|
David D O'Toole CFO |
BUY
Open market or private purchase
|
Direct |
1,000
+9.09%
|
$12,000
$12.88 P/Share
|
|
Aug 21
2023
|
Donna Shiroma General Counsel |
SELL
Open market or private sale
|
Direct |
4,193
-9.03%
|
$62,895
$15.84 P/Share
|
|
Aug 16
2023
|
David D O'Toole CFO |
BUY
Open market or private purchase
|
Direct |
2,000
+10.56%
|
$34,000
$17.05 P/Share
|
|
Aug 15
2023
|
David D O'Toole CFO |
BUY
Open market or private purchase
|
Direct |
5,000
+17.69%
|
$85,000
$17.93 P/Share
|
|
Jun 20
2023
|
David D O'Toole CFO |
BUY
Open market or private purchase
|
Direct |
1,000
+33.33%
|
$16,000
$16.15 P/Share
|
|
Jun 06
2023
|
Cary Guy Vance Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,549
+38.59%
|
-
|
|
Jun 06
2023
|
Robert Mc Namara Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,549
+38.59%
|
-
|
|
Jun 06
2023
|
Lou Panaccio Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,175
+14.23%
|
-
|
|
Jun 06
2023
|
Jan Stern Reed Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,175
+16.27%
|
-
|
|
Jun 06
2023
|
Jeremy Curnock Cook |
BUY
Grant, award, or other acquisition
|
Direct |
6,175
+21.08%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 60.3K shares |
|---|---|
| Open market or private purchase | 16.7K shares |
| Open market or private sale | 8.16K shares |
|---|